{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:44Z","timestamp":1784557004365,"version":"3.55.0"},"reference-count":65,"publisher":"Bioscientifica","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:p>The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major undesired effects of ADT is the concomitant loss of E2, causing among others an increased bone turnover and bone loss and an increased risk of osteoporosis and fractures. Therefore, the guidelines for ADT indicate to combine ADT routinely with bone-sparing agents such as bisphosphonates, denosumab or selective estrogen receptor modulators. However, these compounds may have side effects and some require inconvenient parenteral administration. Co-treatment with estrogens is an alternative approach to prevent bone loss and at the same time, to avoid other side effects caused by the loss of estrogens, which is the topic explored in the present narrative review. Estrogens investigated in PCa patients include parenteral or transdermal E2, diethylstilbestrol (DES), and ethinylestradiol (EE) as monotherapy, or high-dose estetrol (HDE4) combined with ADT. Cardiovascular adverse events have been reported with parenteral E2, DES and EE. Encouraging effects on bone parameters have been obtained with transdermal E2 (tE2) and HDE4, in the tE2 development program (PATCH study), and in the LHRHa\/HDE4 co-treatment study (PCombi), respectively. Confirmation of the beneficial effects of estrogen therapy with tE2 or HDE4 on bone health in patients with advanced PCa is needed, with special emphasis on bone mass and fracture rate.<\/jats:p>","DOI":"10.1530\/ec-22-0182","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:34:30Z","timestamp":1666719270000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":7,"title":["Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review"],"prefix":"10.1530","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-9400","authenticated-orcid":true,"given":"Herjan J T","family":"Coelingh Bennink","sequence":"first","affiliation":[{"name":"Pantarhei Oncology, Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krijgh","sequence":"additional","affiliation":[{"name":"Pantarhei Oncology, Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan F M","family":"Egberts","sequence":"additional","affiliation":[{"name":"Terminal 4 Communications, Hilversum, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Slootweg","sequence":"additional","affiliation":[{"name":"Independent Consultant, Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H E","family":"van Melick","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P M","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Urology, Antonius Hospital, Sneek, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M","family":"Somford","sequence":"additional","affiliation":[{"name":"Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Pantarhei Oncology, Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman J","family":"Schultz","sequence":"additional","affiliation":[{"name":"Pantarhei Oncology, Zeist, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W","family":"Clarke","sequence":"additional","affiliation":[{"name":"The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Jeroen A","family":"van Moorselaar","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam UMC, VU University, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M J","family":"Debruyne","sequence":"additional","affiliation":[{"name":"Andros Clinics, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","unstructured":"Shore NDSaad FCookson MSGeorge DJSaltzstein DRTutrone RAkaza HBossi Avan Veenhuyzen DFSelby B, Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine20203822187\u20132196. (https:\/\/doi.org\/10.1056\/NEJMoa2004325)10.1056\/NEJMoa2004325"},{"key":"bib2","series-title":"Prostate","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","unstructured":"Shore NDAntonarakis ESCookson MSCrawford EDMorgans AKAlbala DMHafron JHarris RGSaltzstein DBrown GA, Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate202080527\u2013544. (https:\/\/doi.org\/10.1002\/pros.23967)10.1002\/pros.23967"},{"key":"bib3","series-title":"British Journal of Cancer","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"Bourke","year":"2013","unstructured":"Bourke LKirkbride PHooper RRosario AJChico TJRosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?British Journal of Cancer20131089\u201313. (https:\/\/doi.org\/10.1038\/bjc.2012.523)10.1038\/bjc.2012.523"},{"key":"bib4","series-title":"New England Journal of Medicine","first-page":"1281","article-title":"Leuprolide versus diethylstilbestrol for metastatic prostate cancer","volume":"311","year":"1984","unstructured":"Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine19843111281\u20131286. (https:\/\/doi.org\/10.1056\/NEJM198411153112004)"},{"key":"bib5","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","unstructured":"Klotz LBoccon-Gibod LShore NDAndreou CPersson BECantor PJensen JKOlesen TKSchroder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International20081021531\u20131538. (https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08183.x)10.1111\/j.1464-410X.2008.08183.x"},{"key":"bib6","series-title":"Oncology and Therapy","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting","volume":"8","author":"Ng","year":"2020","unstructured":"Ng KSmith SShamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncology and Therapy20208209\u2013230. (https:\/\/doi.org\/10.1007\/s40487-020-00119-z)10.1007\/s40487-020-00119-z"},{"key":"bib7","series-title":"Prostate Cancer and Prostatic Diseases","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","unstructured":"Crawford EDHeidenreich ALawrentschuk NTombal BPompeo ACLMendoza-Valdes AMiller KDebruyne FMJKlotz L. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases20192224\u201338. (https:\/\/doi.org\/10.1038\/s41391-018-0079-0)10.1038\/s41391-018-0079-0"},{"key":"bib8","series-title":"Psychooncology","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/pon.1401","article-title":"Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer","volume":"18","author":"Cherrier","year":"2009","unstructured":"Cherrier MMAubin SHigano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology200918237\u2013247. (https:\/\/doi.org\/10.1002\/pon.1401)10.1002\/pon.1401"},{"key":"bib9","series-title":"Frontiers in Oncology","article-title":"Bone fracture incidence after androgen deprivation therapy-investigational agents: results from cancer therapy evaluation program-sponsored early phase clinical trials 2006\u20132013","volume":"10","author":"Myint","year":"2020","unstructured":"Myint ZWKunos CA. Bone fracture incidence after androgen deprivation therapy-investigational agents: results from cancer therapy evaluation program-sponsored early phase clinical trials 2006\u20132013. Frontiers in Oncology202010 1125. (https:\/\/doi.org\/10.3389\/fonc.2020.01125)"},{"key":"bib10","series-title":"Journal of Clinical Medicine","article-title":"Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Kim","year":"2019","unstructured":"Kim DKLee JYKim KJHong NKim JWHah YSKoo KCKim JHCho KS. Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis. Journal of Clinical Medicine20198 113. (https:\/\/doi.org\/10.3390\/jcm8010113)"},{"key":"bib11","series-title":"Journal of Bone and Mineral Research","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/jbmr.405","article-title":"Fracture risk in men with prostate cancer: a population-based study","volume":"26","author":"Melton","year":"2011","unstructured":"Melton 3rd LJLieber MMAtkinson EJAchenbach SJZincke HTherneau TMKhosla S. Fracture risk in men with prostate cancer: a population-based study. Journal of Bone and Mineral Research2011261808\u20131815. (https:\/\/doi.org\/10.1002\/jbmr.405)10.1002\/jbmr.405"},{"key":"bib12","series-title":"PLoS ONE","article-title":"Mortality following hip fracture in men with prostate cancer","volume":"8","author":"Van Hemelrijck","year":"2013","unstructured":"Van Hemelrijck MGarmo HMichaelsson KThorstenson AAkre OStattin PHolmberg LAdolfsson J. Mortality following hip fracture in men with prostate cancer. PLoS ONE20138 e74492. (https:\/\/doi.org\/10.1371\/journal.pone.0074492)"},{"key":"bib13","series-title":"European Urology Oncology","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","article-title":"Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"2","author":"Joseph","year":"2019","unstructured":"Joseph JSLam VPatel MI. Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. European Urology Oncology20192551\u2013561. (https:\/\/doi.org\/10.1016\/j.euo.2018.11.001)10.1016\/j.euo.2018.11.001"},{"key":"bib14","series-title":"Mayo Clinic Proceedings","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","unstructured":"Kennel KADrake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clinic Proceedings200984632\u2013637; quiz 638. (https:\/\/doi.org\/10.1016\/S0025-6196(1160752-0)10.1016\/S0025-6196(11)60752-0"},{"key":"bib15","series-title":"Expert Opinion on Drug Safety","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/14740338.2021.1861246","article-title":"The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn","volume":"20","author":"Deligiorgi","year":"2021","unstructured":"Deligiorgi MVTrafalis DT. The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. Expert Opinion on Drug Safety202120191\u2013213. (https:\/\/doi.org\/10.1080\/14740338.2021.1861246)10.1080\/14740338.2021.1861246"},{"key":"bib16","series-title":"Aging Male","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/13685538.2018.1448058","article-title":"The use of selective estrogen receptor modulators on bone health in men","volume":"22","author":"Wong","year":"2019","unstructured":"Wong SKMohamad NVJayusman PAShuid ANIma-Nirwana SChin KY. The use of selective estrogen receptor modulators on bone health in men. Aging Male20192289\u2013101. (https:\/\/doi.org\/10.1080\/13685538.2018.1448058)10.1080\/13685538.2018.1448058"},{"key":"bib17","series-title":"Reviews in Urology","first-page":"163","article-title":"Estrogenic side effects of androgen deprivation therapy","volume":"9","author":"Guise","year":"2007","unstructured":"Guise TAOefelein MGEastham JACookson MSHigano CSSmith MR. Estrogenic side effects of androgen deprivation therapy. Reviews in Urology20079163\u2013180."},{"key":"bib18","series-title":"British Journal of Cancer","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.bjc.6604230","article-title":"Parenteral oestrogen in the treatment of prostate cancer: a systematic review","volume":"98","author":"Norman","year":"2008","unstructured":"Norman GDean MELangley REHodges ZCRitchie GParmar MKSydes MRAbel PEastwood AJ. Parenteral oestrogen in the treatment of prostate cancer: a systematic review. British Journal of Cancer200898697\u2013707. (https:\/\/doi.org\/10.1038\/sj.bjc.6604230)10.1038\/sj.bjc.6604230"},{"key":"bib19","series-title":"Indian Journal of Urology","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/iju.IJU_56_19","article-title":"The resurgence of estrogens in the treatment of castration-resistant prostate cancer","volume":"35","author":"Moorthy","year":"2019","unstructured":"Moorthy HKLaxman Prabhu GGVenugopal P. The resurgence of estrogens in the treatment of castration-resistant prostate cancer. Indian Journal of Urology201935189\u2013196. (https:\/\/doi.org\/10.4103\/iju.IJU_56_19)10.4103\/iju.IJU_56_19"},{"key":"bib20","series-title":"European Urology","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.eururo.2015.11.030","article-title":"A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol","volume":"69","author":"Langley","year":"2016","unstructured":"Langley REKynaston HGAlhasso AADuong TPaez EMJovic GScrase CDRobertson ACafferty FWelland A, A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. European Urology2016691016\u20131025. (https:\/\/doi.org\/10.1016\/j.eururo.2015.11.030)10.1016\/j.eururo.2015.11.030"},{"key":"bib21","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/ERC-17-0153","article-title":"Estradiol for the mitigation of adverse effects of androgen deprivation therapy","volume":"24","author":"Russell","year":"2017","unstructured":"Russell NCheung AGrossmann M. Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocrine-Related Cancer201724R297\u2013R313. (https:\/\/doi.org\/10.1530\/ERC-17-0153)10.1530\/ERC-17-0153"},{"key":"bib22","series-title":"International Urology and Nephrology","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s11255-018-1854-5","article-title":"Estrogen therapy in patients with prostate cancer: a contemporary systematic review","volume":"50","author":"Reis","year":"2018","unstructured":"Reis LOZani ELGarcia-Perdomo HA. Estrogen therapy in patients with prostate cancer: a contemporary systematic review. International Urology and Nephrology201850993\u20131003. (https:\/\/doi.org\/10.1007\/s11255-018-1854-5)10.1007\/s11255-018-1854-5"},{"key":"bib23","series-title":"International Journal of Urology","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/iju.12613","article-title":"Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience","volume":"22","author":"Sciarra","year":"2015","unstructured":"Sciarra AGentile VCattarino SGentilucci AAlfarone AD'Eramo GSalciccia S. Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience. International Journal of Urology20152298\u2013103. (https:\/\/doi.org\/10.1111\/iju.12613)10.1111\/iju.12613"},{"key":"bib24","series-title":"Menopause","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/GME.0000000000000823","article-title":"Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study","volume":"24","author":"Coelingh Bennink","year":"2017","unstructured":"Coelingh Bennink HJTVerhoeven CZimmerman YVisser MFoidart JMGemzell-Danielsson K. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study. Menopause201724677\u2013685. (https:\/\/doi.org\/10.1097\/GME.0000000000000823)10.1097\/GME.0000000000000823"},{"key":"bib25","series-title":"European Urology Open Science","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2021.04.005","article-title":"Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi)","volume":"28","author":"Coelingh Bennink","year":"2021","unstructured":"Coelingh Bennink HJTVan Moorselaar JACrawford EDRoos EPMSomford DMRoeleveld TADe Haan TDVan Melick HHEReisman YZimmerman Y, Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi). European Urology Open Science20212852\u201361. (https:\/\/doi.org\/10.1016\/j.euros.2021.04.005)10.1016\/j.euros.2021.04.005"},{"key":"bib26","series-title":"Prostate Cancer and Prostatic Diseases","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2021","unstructured":"Hussain ATripathi APieczonka CCope DMcNatty ALogothetis CGuise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases202124290\u2013300. (https:\/\/doi.org\/10.1038\/s41391-020-00296-y)10.1038\/s41391-020-00296-y"},{"key":"bib27","series-title":"Trends in Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tem.2020.12.004","article-title":"Effects of medical treatment of prostate cancer on bone health","volume":"32","author":"Formenti","year":"2021","unstructured":"Formenti AMDalla Volta Adi Filippo LBerruti AGiustina A. Effects of medical treatment of prostate cancer on bone health. Trends in Endocrinology and Metabolism202132135\u2013158. (https:\/\/doi.org\/10.1016\/j.tem.2020.12.004)10.1016\/j.tem.2020.12.004"},{"key":"bib28","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline","volume":"38","author":"Saylor","year":"2020","unstructured":"Saylor PJRumble RBTagawa SEastham JAFinelli AReddy PSKungel TMNissenberg MGMichalski JM. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline. Journal of Clinical Oncology2020381736\u20131743. (https:\/\/doi.org\/10.1200\/JCO.19.03148)10.1200\/JCO.19.03148"},{"key":"bib29","series-title":"ESMO Open","article-title":"Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion","volume":"5","author":"Santini","year":"2020","unstructured":"Santini DBerruti ADi Maio MProcopio GBracarda SIbrahim TBertoldo F. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open20205 e000652. (https:\/\/doi.org\/10.1136\/esmoopen-2019-000652)"},{"key":"bib30","series-title":"Cold Spring Harbor Perspectives in Medicine","article-title":"Regulation of bone metabolism by sex steroids","volume":"8","author":"Khosla","year":"2018","unstructured":"Khosla SMonroe DG. Regulation of bone metabolism by sex steroids. Cold Spring Harbor Perspectives in Medicine20188 a031211. (https:\/\/doi.org\/10.1101\/cshperspect.a031211)"},{"key":"bib31","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1210\/jc.2009-2635","article-title":"Osteoporotic fractures in men study research G. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study","volume":"95","author":"Cauley","year":"2010","unstructured":"Cauley JAEwing SKTaylor BCFink HAEnsrud KEBauer DCBarrett-Connor EMarshall LOrwoll ES & Osteoporotic Fractures in Men Study (MrOS) Research Group. Osteoporotic fractures in men study research G. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study. Journal of Clinical Endocrinology and Metabolism2010954314\u20134323. (https:\/\/doi.org\/10.1210\/jc.2009-2635)10.1210\/jc.2009-2635"},{"key":"bib32","series-title":"Frontiers in Neuroendocrinology","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.yfrne.2021.100926","article-title":"On the role of sex steroids in biological functions by classical and non-classical pathways. an update","volume":"62","author":"Pillerova","year":"2021","unstructured":"Pillerova MBorbelyova VHodosy JRiljak VRenczes EFrick KMTothova \u013d. On the role of sex steroids in biological functions by classical and non-classical pathways. an update. Frontiers in Neuroendocrinology202162100926. (https:\/\/doi.org\/10.1016\/j.yfrne.2021.100926)10.1016\/j.yfrne.2021.100926"},{"key":"bib33","series-title":"Clinical Biochemist Reviews","first-page":"3","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey","year":"2016","unstructured":"Davey RAGrossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clinical Biochemist Reviews2016373\u201315."},{"key":"bib34","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","article-title":"Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man","volume":"331","author":"Smith","year":"1994","unstructured":"Smith EPBoyd JFrank GRTakahashi HCohen RMSpecker BWilliams TCLubahn DBKorach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England Journal of Medicine19943311056\u20131061. (https:\/\/doi.org\/10.1056\/NEJM199410203311604)10.1056\/NEJM199410203311604"},{"key":"bib35","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3689","article-title":"Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens","volume":"80","author":"Morishima","year":"1995","unstructured":"Morishima AGrumbach MMSimpson ERFisher CQin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Journal of Clinical Endocrinology and Metabolism1995803689\u20133698. (https:\/\/doi.org\/10.1210\/jcem.80.12.8530621)"},{"key":"bib36","series-title":"Journal of Clinical Investigation","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","unstructured":"Falahati-Nini ARiggs BLAtkinson EJO'Fallon WMEastell RKhosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. Journal of Clinical Investigation20001061553\u20131560. (https:\/\/doi.org\/10.1172\/JCI10942)10.1172\/JCI10942"},{"key":"bib37","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1210\/jc.2009-0206","article-title":"The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men","volume":"94","author":"LeBlanc","year":"2009","unstructured":"LeBlanc ESNielson CMMarshall LMLapidus JABarrett-Connor EEnsrud KEHoffman ARLaughlin GOhlsson COrwoll ES, The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. Journal of Clinical Endocrinology and Metabolism2009943337\u20133346. (https:\/\/doi.org\/10.1210\/jc.2009-0206)10.1210\/jc.2009-0206"},{"key":"bib38","series-title":"Endocrine Reviews","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1210\/er.2014-1024","article-title":"Sex steroid actions in male bone","volume":"35","author":"Vanderschueren","year":"2014","unstructured":"Vanderschueren DLaurent MRClaessens FGielen ELagerquist MKVandenput LBorjesson AEOhlsson C. Sex steroid actions in male bone. Endocrine Reviews201435906\u2013960. (https:\/\/doi.org\/10.1210\/er.2014-1024)10.1210\/er.2014-1024"},{"key":"bib39","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","unstructured":"Greenspan SLCoates PSereika SMNelson JBTrump DLResnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism2005906410\u20136417. (https:\/\/doi.org\/10.1210\/jc.2005-0183)10.1210\/jc.2005-0183"},{"key":"bib40","series-title":"Scandinavian Journal of Urology and Nephrology","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/00365590801943274","article-title":"Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5","volume":"42","author":"Hedlund","year":"2008","unstructured":"Hedlund PODamber JEHagerman IHaukaas SHenriksson PIversen PJohansson RKlarskov PLundbeck FRasmussen F, Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology200842220\u2013229. (https:\/\/doi.org\/10.1080\/00365590801943274)10.1080\/00365590801943274"},{"key":"bib41","series-title":"Women\u2019s Health","first-page":"815","article-title":"The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis","volume":"11","author":"Bertonazzi","year":"2015","unstructured":"Bertonazzi ANelson BSalvador JUmland E. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. Women\u2019s Health201511815\u2013824. (https:\/\/doi.org\/10.2217\/whe.15.64)"},{"key":"bib42","series-title":"Journal of Urology","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/01.ju.0000061024.75334.40","article-title":"Transdermal estradiol therapy for advanced prostate cancer--forward to the past?","volume":"169","author":"Ockrim","year":"2003","unstructured":"Ockrim JLLalani ENLaniado MECarter SSAbel PD. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?Journal of Urology20031691735\u20131737. (https:\/\/doi.org\/10.1097\/01.ju.0000061024.75334.40)10.1097\/01.ju.0000061024.75334.40"},{"key":"bib43","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1530\/EJE-17-1072","article-title":"Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial","volume":"178","author":"Russell","year":"2018","unstructured":"Russell NHoermann RCheung ASChing MZajac JDHandelsman DJGrossmann M. Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. European Journal of Endocrinology2018178565\u2013576. (https:\/\/doi.org\/10.1530\/EJE-17-1072)10.1530\/EJE-17-1072"},{"key":"bib44","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the prostate adenocarcinoma: transcutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","unstructured":"Gilbert DCDuong TKynaston HGAlhasso AACafferty FHRosen SDKanaga-Sundaram SDixit SLaniado MMadaan S, Quality-of-life outcomes from the prostate adenocarcinoma: transcutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU International2017119667\u2013675. (https:\/\/doi.org\/10.1111\/bju.13687)10.1111\/bju.13687"},{"key":"bib45","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","unstructured":"Langley REGilbert DCDuong TClarke NWNankivell MRosen SDMangar SMacnair ASundaram SKLaniado ME, Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet2021397581\u2013591.10.1016\/S0140-6736(21)00100-8"},{"key":"bib46","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"E826","DOI":"10.1111\/j.1464-410X.2012.11206.x","article-title":"Current role of diethylstilbestrol in the management of advanced prostate cancer","volume":"110","author":"Bosset","year":"2012","unstructured":"Bosset POAlbiges LSeisen Tde la Motte Rouge TPhe VBitker MORoupret M. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU International2012110E826\u2013E829. (https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11206.x)10.1111\/j.1464-410X.2012.11206.x"},{"key":"bib47","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"E727","DOI":"10.1111\/j.1464-410X.2012.11546.x","article-title":"Diethylstilbestrol in castration-resistant prostate cancer","volume":"110","author":"Wilkins","year":"2012","unstructured":"Wilkins AShahidi MParker CGunapala RThomas KHuddart RHorwich ADearnaley D. Diethylstilbestrol in castration-resistant prostate cancer. BJU International2012110E727\u2013E735. (https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11546.x)10.1111\/j.1464-410X.2012.11546.x"},{"key":"bib48","series-title":"Anticancer Research","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.21873\/anticanres.14194","article-title":"Therapeutic effect of ethinylestradiol in castration-resistant prostate cancer","volume":"40","author":"Nakano","year":"2020","unstructured":"Nakano TKadono YIwamoto HYaegashi HIijima MKawaguchi SNohara TShigehara KIzumi KMizokami A. Therapeutic effect of ethinylestradiol in castration-resistant prostate cancer. Anticancer Research2020402291\u20132296. (https:\/\/doi.org\/10.21873\/anticanres.14194)10.21873\/anticanres.14194"},{"key":"bib49","series-title":"Clinical Genitourinary Cancer","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.clgc.2016.08.024","article-title":"Low-dose oral ethinylestradiol With concomitant low-dose acetylsalicylic acid for advanced castrate-resistant prostate cancer","volume":"15","author":"Roviello","year":"2017","unstructured":"Roviello GZanotti LGobbi ADester MGenerali DPacifico CCappelletti MRBonetta A. Low-dose oral ethinylestradiol With concomitant low-dose acetylsalicylic acid for advanced castrate-resistant prostate cancer. Clinical Genitourinary Cancer201715371\u2013375. (https:\/\/doi.org\/10.1016\/j.clgc.2016.08.024)10.1016\/j.clgc.2016.08.024"},{"key":"bib50","series-title":"Anticancer Research","first-page":"2999","article-title":"Efficacy of ethinylestradiol re-challenge for metastatic castration-resistant prostate cancer","volume":"36","author":"Onishi","year":"2016","unstructured":"Onishi TShibahara TMasui SSugino YHigashi SSasaki T. Efficacy of ethinylestradiol re-challenge for metastatic castration-resistant prostate cancer. Anticancer Research2016362999\u20133004."},{"key":"bib51","series-title":"Acta Endocrinologica","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/acta.0.0490207","article-title":"Metabolism of 17-beta-oestradiol-4-14-C in early infancy","volume":"49","author":"Hagen","year":"1965","unstructured":"Hagen AABarr MDiczfalusy E. Metabolism of 17-beta-oestradiol-4-14-C in early infancy. Acta Endocrinologica196549207\u2013220. (https:\/\/doi.org\/10.1530\/acta.0.0490207)10.1530\/acta.0.0490207"},{"issue":"Supplement 1","key":"bib52","series-title":"Climacteric","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/13697130802073425","article-title":"Estetrol review: profile and potential clinical applications","volume":"11","author":"Coelingh Bennink","year":"2008","unstructured":"Coelingh Bennink HJHolinka CFDiczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric200811(Supplement 1) 47\u201358. (https:\/\/doi.org\/10.1080\/13697130802073425)10.1080\/13697130802073425"},{"issue":"Supplement 1","key":"bib53","series-title":"Climacteric","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/13697130701851814","article-title":"Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells","volume":"11","author":"Hammond","year":"2008","unstructured":"Hammond GLHogeveen KNVisser MCoelingh Bennink HJ. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric200811(Supplement 1) 41\u201346. (https:\/\/doi.org\/10.1080\/13697130701851814)10.1080\/13697130701851814"},{"key":"bib54","series-title":"Expert Review of Clinical Pharmacology","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"Gerard","year":"2022","unstructured":"Gerard CArnal JFJost MDouxfils JLenfant FFontaine CHoutman RArcher DFReid RLLobo RA, Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology202215121\u2013137. (https:\/\/doi.org\/10.1080\/17512433.2022.2054413)10.1080\/17512433.2022.2054413"},{"issue":"Supplement 1","key":"bib55","series-title":"Climacteric","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/13697130802050340","article-title":"In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism","volume":"11","author":"Visser","year":"2008","unstructured":"Visser MFoidart JMCoelingh Bennink HJ. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric200811(Supplement 1) 64\u201368. (https:\/\/doi.org\/10.1080\/13697130802050340)10.1080\/13697130802050340"},{"key":"bib56","series-title":"Research and Reports in Urology","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/RRU.S157116","article-title":"Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens","volume":"10","author":"Ito","year":"2018","unstructured":"Ito YSadar MD. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. Research and Reports in Urology20181023\u201332. (https:\/\/doi.org\/10.2147\/RRU.S157116)10.2147\/RRU.S157116"},{"issue":"Supplement 1","key":"bib57","series-title":"Climacteric","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/13697130701798692","article-title":"Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model","volume":"11","author":"Coelingh Bennink","year":"2008","unstructured":"Coelingh Bennink HJHeegaard AMVisser MHolinka CFChristiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric200811(Supplement 1) 2\u201314. (https:\/\/doi.org\/10.1080\/13697130701798692)10.1080\/13697130701798692"},{"key":"bib58","series-title":"Contraception","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","unstructured":"Douxfils JKlipping CDuijkers IKinet VMawet MMaillard CJost MRosing JFoidart JM. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception2020102396\u2013402. (https:\/\/doi.org\/10.1016\/j.contraception.2020.08.015)10.1016\/j.contraception.2020.08.015"},{"key":"bib59","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1210\/jc.2018-00147","article-title":"A dose-escalating study with the fetal estrogen estetrol in healthy men","volume":"103","author":"Coelingh Bennink","year":"2018","unstructured":"Coelingh Bennink HJTZimmerman YVerhoeven CDutman AEMensinga TKluft CReisman YDebruyne FMJ. A dose-escalating study with the fetal estrogen estetrol in healthy men. Journal of Clinical Endocrinology and Metabolism20181033239\u20133249. (https:\/\/doi.org\/10.1210\/jc.2018-00147)10.1210\/jc.2018-00147"},{"key":"bib60","series-title":"Climacteric","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/13697137.2021.1965117","article-title":"Breast cancer therapy and bone","volume":"25","author":"Stevens","year":"2022","unstructured":"Stevens ZHellig J. Breast cancer therapy and bone. Climacteric20222567\u201372. (https:\/\/doi.org\/10.1080\/13697137.2021.1965117)10.1080\/13697137.2021.1965117"},{"key":"bib61","series-title":"Annals of Internal Medicine","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/M16-2577","article-title":"Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis","volume":"167","author":"Alibhai","year":"2017","unstructured":"Alibhai SMHZukotynski KWalker-Dilks CEmmenegger UFinelli AMorgan SCHotte SJTomlinson GAWinquist E. Bone health and bone-targeted therapies for nonmetastatic prostate cancer: a systematic review and meta-analysis. Annals of Internal Medicine2017167341\u2013350. (https:\/\/doi.org\/10.7326\/M16-2577)10.7326\/M16-2577"},{"key":"bib62","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bju.14015","article-title":"Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures","volume":"121","author":"Poon","year":"2018","unstructured":"Poon YPechlivanoglou PAlibhai SMHNaimark DHoch JSPapadimitropoulos EHogan MEKrahn M. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU International201812117\u201328. (https:\/\/doi.org\/10.1111\/bju.14015)10.1111\/bju.14015"},{"key":"bib63","series-title":"Contraception","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (Fiesta)","volume":"94","author":"Apter","year":"2016","unstructured":"Apter DZimmerman YBeekman LMawet MMaillard CFoidart JMBennink HJ. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (Fiesta). Contraception201694366\u2013373. (https:\/\/doi.org\/10.1016\/j.contraception.2016.04.015)10.1016\/j.contraception.2016.04.015"},{"key":"bib64","series-title":"BJOG","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern, and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","unstructured":"Gemzell-Danielsson KApter DZatik JWeyers SPiltonen TSuturina LApolikhina IJost MCreinin MDFoidart JM. Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern, and safety in Europe and Russia. BJOG202212963\u201371. (https:\/\/doi.org\/10.1111\/1471-0528.16840)10.1111\/1471-0528.16840"},{"key":"bib65","series-title":"Menopause","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/GME.0000000000001561","article-title":"A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety","volume":"27","author":"Gaspard","year":"2020","unstructured":"Gaspard UTaziaux MMawet MJost MGordenne VCoelingh Bennink HJTLobo RAUtian WHFoidart JM. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause202027848\u2013857. (https:\/\/doi.org\/10.1097\/GME.0000000000001561)10.1097\/GME.0000000000001561"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/11\/12\/EC-22-0182.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/12\/EC-22-0182.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/12\/EC-22-0182.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:40Z","timestamp":1784555140000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":65,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/ec-22-0182","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}